ResearcherHarvard UniversityActive in the last 2 years
Priyadarshini Pathak
Matched on ORCID iD 0009-0008-9269-3583; OpenAlex author ID A5102889823, A5122836711. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 37
2024: 3 papers · 2025: none · 2026: 2 papers
Papers 5
- Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
- Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-25-2052↗
- The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma-Progress or Passive Acceptance? Co-author DOI 10.1001/jamaoncol.2024.0870↗
- Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(24)00290-0↗
- Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
Closest collaborators
The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Colin D. Weekes · 5 shared papers, 2024–2026 · strength 1.29
- Paper The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma-Progress or Passive Acceptance? DOI 10.1001/jamaoncol.2024.0870↗
- Paper Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer. DOI 10.1016/s1470-2045(24)00290-0↗
- Paper Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.3716↗
- Jennifer Yon-Li Wo · 3 shared papers, 2024–2026 · strength 0.73
- Paper Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer. DOI 10.1016/s1470-2045(24)00290-0↗
- Paper Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.3716↗
- Paper Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenoc… DOI 10.1097/sla.0000000000006131↗
- Lawrence Scott Blaszkowsky · 3 shared papers, 2024–2026 · strength 0.57
- Paper Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.3716↗
- Paper Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-25-2052↗
- Paper Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenoc… DOI 10.1097/sla.0000000000006131↗
- Theodore Sunki Hong · 2 shared papers, 2024–2026 · strength 0.37
- Hannah Johnson Roberts · 2 shared papers, 2024–2026 · strength 0.37
- David P. Ryan · 2 shared papers, 2024–2026 · strength 0.37
- Motaz Qadan · 2 shared papers, 2024–2026 · strength 0.37
- Keith D. Lillemoe · 2 shared papers, 2024–2026 · strength 0.37
- Aparna R. Parikh · 2 shared papers, 2024–2026 · strength 0.37
- Rachna T. Shroff · 1 shared paper, 2024 · strength 0.36
- Carlos Fernández-del Castillo · 1 shared paper, 2026 · strength 0.20
- Giulio Belfiori · 1 shared paper, 2026 · strength 0.20
- Stefano Partelli · 1 shared paper, 2026 · strength 0.20
- Federico De Stefano · 1 shared paper, 2026 · strength 0.20
- Nicolò Pecorelli · 1 shared paper, 2026 · strength 0.20
- Diego Palumbo · 1 shared paper, 2026 · strength 0.20
- Domenico Tamburrino · 1 shared paper, 2026 · strength 0.20
- Giulia Gasparini · 1 shared paper, 2026 · strength 0.20
- Francesco DE COBELLI · 1 shared paper, 2026 · strength 0.20
- Jon Michael Harrison · 1 shared paper, 2026 · strength 0.20
- Gianpaolo Balzano · 1 shared paper, 2026 · strength 0.20
- Massimo Falconi · 1 shared paper, 2026 · strength 0.20
- Marco Schiavo Lena · 1 shared paper, 2026 · strength 0.20
- Stefano Crippa · 1 shared paper, 2026 · strength 0.20
- David Tsai Ting · 1 shared paper, 2026 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.